FY2026 Earnings Estimate for Nevro Issued By William Blair

Nevro Corp. (NYSE:NVRO) – Investment analysts at William Blair issued their FY2026 EPS estimates for shares of Nevro in a research note issued to investors on Tuesday, November 12th. William Blair analyst B. Vazquez expects that the medical equipment provider will earn ($2.46) per share for the year. The consensus estimate for Nevro’s current full-year earnings is ($2.60) per share.

Nevro (NYSE:NVRO) last posted its quarterly earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.40. The business had revenue of $96.60 million during the quarter, compared to analyst estimates of $93.09 million. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.35%. The company’s revenue was down 7.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.65) earnings per share.

A number of other equities analysts have also weighed in on the company. Wells Fargo & Company lowered Nevro from an “equal weight” rating to an “underweight” rating and dropped their price objective for the stock from $13.00 to $5.50 in a research note on Wednesday, August 7th. Citigroup cut their price objective on shares of Nevro from $6.89 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, October 1st. Truist Financial lowered their target price on shares of Nevro from $10.00 to $5.50 and set a “hold” rating on the stock in a report on Thursday, August 8th. JMP Securities reaffirmed a “market perform” rating on shares of Nevro in a research note on Tuesday. Finally, Canaccord Genuity Group decreased their price target on shares of Nevro from $8.00 to $7.00 and set a “hold” rating on the stock in a research note on Tuesday. Three research analysts have rated the stock with a sell rating and twelve have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.10.

Nevro Trading Down 12.1 %

Shares of NVRO stock opened at $4.45 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.53 and a current ratio of 4.77. The stock has a fifty day simple moving average of $5.23 and a two-hundred day simple moving average of $7.44. The firm has a market capitalization of $165.91 million, a PE ratio of -2.35 and a beta of 0.93. Nevro has a 52-week low of $4.38 and a 52-week high of $22.64.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NVRO. Armistice Capital LLC increased its stake in Nevro by 1.3% during the second quarter. Armistice Capital LLC now owns 3,672,000 shares of the medical equipment provider’s stock worth $30,918,000 after acquiring an additional 48,000 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Nevro by 21.4% in the 2nd quarter. Millennium Management LLC now owns 956,542 shares of the medical equipment provider’s stock worth $8,054,000 after purchasing an additional 168,573 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Nevro by 27.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 929,348 shares of the medical equipment provider’s stock worth $5,195,000 after purchasing an additional 200,885 shares during the period. Renaissance Technologies LLC increased its position in shares of Nevro by 5.0% during the 2nd quarter. Renaissance Technologies LLC now owns 368,100 shares of the medical equipment provider’s stock valued at $3,099,000 after purchasing an additional 17,600 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Nevro by 3.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 303,675 shares of the medical equipment provider’s stock valued at $1,698,000 after buying an additional 11,369 shares during the period. Institutional investors own 95.52% of the company’s stock.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.